Demant A/S (WDH1) Stock Forecast, Price Targets and Analysts Predictions

WDH1 Analyst Ratings

Moderate Buy

5 Buy

5 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Demant

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

WDH1 Stock 12 Month Forecast

Average Price Target

―

Based on 10 Wall Street analysts offering 12 month price targets for Demant in the last 3 months. The average price target is CHF36.55 with a high forecast of CHF43.33 and a low forecast of CHF32.40. The average price target represents a ― change from the last price of ―.

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

Highest Price TargetCHF43.33

Average Price TargetCHF36.55

Lowest Price TargetCHF32.40

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Martinien Rula

Jefferies

CHF36.42→CHF43.33

Buy

―

Reiterated

08/20/26

Jefferies Reaffirms Their Buy Rating on Demant (WILLF)

Susannah Ludwig

Bernstein

CHF34.66

Hold

―

Reiterated

08/14/26

Bernstein Remains a Hold on Demant (WILLF)

Veronika Dubajova

Citi

―

Buy

―

Reiterated

08/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Achieve Life Sciences (NASDAQ: ACHV), Mereo Biopharma Group Plc (NASDAQ: MREO) and Demant (Other OTC: WILLF)

Richard Felton

Goldman Sachs

CHF36.42→CHF41.44

Buy

―

Assigned

08/13/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Forte Biosciences (NASDAQ: FBRX) and Demant (Other OTC: WILLF)

Aisyah Noor

Morgan Stanley

CHF36.42→CHF37.17

Buy

―

Reiterated

08/13/26

Morgan Stanley Remains a Buy on Demant (WILLF)

Hassan Al-Wakeel

Barclays

CHF30.14→CHF33.91

Hold

―

Reiterated

08/13/26

Demant (WILLF) Gets a Hold from Barclays

Unknown Analyst

Danske Bank

Not Ranked

Danske Bank

CHF35.16

Hold

―

Downgraded

08/06/26

Demant downgraded to Hold from Buy at Danske BankDemant downgraded to Hold from Buy at Danske Bank

Kavya Deshpande

UBS

CHF34.28→CHF35.67

Hold

―

Downgraded

07/22/26

Demant downgraded to Neutral from Buy at UBSDemant downgraded to Neutral from Buy at UBS

Falko Friedrichs

Deutsche Bank

CHF28.38→CHF32.4

Hold

―

Reiterated

07/06/26

Demant price target raised to DKK 258 from DKK 226 at Deutsche BankDemant price target raised to DKK 258 from DKK 226 at Deutsche Bank

Julien Ouaddour

Bank of America Securities

CHF21.35→CHF35.16

Buy

―

Upgraded

06/09/26

Demant upgraded to Buy from Underperform at BofADemant upgraded to Buy from Underperform at BofA

Martin Brenoe

Nordea Markets

CHF28.88

Buy

―

Upgraded

02/18/26

Demant upgraded to Buy from Hold at NordeaDemant upgraded to Buy from Hold at Nordea

Andjela Bozinovic

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

CHF25.12

Hold

―

Downgraded

02/06/26

Demant downgraded to Neutral from Outperform at BNP ParibasDemant downgraded to Neutral from Outperform at BNP Paribas

David Adlington

J.P. Morgan

CHF36.17→CHF31.4

Buy

―

Reiterated

02/04/26

Demant price target lowered to DKK 250 from DKK 288 at JPMorganDemant price target lowered to DKK 250 from DKK 288 at JPMorgan

Jack Reynolds-Clark

RBC Capital

CHF31.4

Hold

―

Initiated

11/18/25

Demant initiated with a Sector Perform at RBC CapitalDemant initiated with a Sector Perform at RBC Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Martinien Rula

Jefferies

CHF36.42→CHF43.33

Buy

―

Reiterated

08/20/26

Jefferies Reaffirms Their Buy Rating on Demant (WILLF)

Susannah Ludwig

Bernstein

CHF34.66

Hold

―

Reiterated

08/14/26

Bernstein Remains a Hold on Demant (WILLF)

Veronika Dubajova

Citi

―

Buy

―

Reiterated

08/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Achieve Life Sciences (NASDAQ: ACHV), Mereo Biopharma Group Plc (NASDAQ: MREO) and Demant (Other OTC: WILLF)

Richard Felton

Goldman Sachs

CHF36.42→CHF41.44

Buy

―

Assigned

08/13/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Forte Biosciences (NASDAQ: FBRX) and Demant (Other OTC: WILLF)

Aisyah Noor

Morgan Stanley

CHF36.42→CHF37.17

Buy

―

Reiterated

08/13/26

Morgan Stanley Remains a Buy on Demant (WILLF)

Hassan Al-Wakeel

Barclays

CHF30.14→CHF33.91

Hold

―

Reiterated

08/13/26

Demant (WILLF) Gets a Hold from Barclays

Unknown Analyst

Danske Bank

Not Ranked

Danske Bank

CHF35.16

Hold

―

Downgraded

08/06/26

Demant downgraded to Hold from Buy at Danske BankDemant downgraded to Hold from Buy at Danske Bank

Kavya Deshpande

UBS

CHF34.28→CHF35.67

Hold

―

Downgraded

07/22/26

Demant downgraded to Neutral from Buy at UBSDemant downgraded to Neutral from Buy at UBS

Falko Friedrichs

Deutsche Bank

CHF28.38→CHF32.4

Hold

―

Reiterated

07/06/26

Demant price target raised to DKK 258 from DKK 226 at Deutsche BankDemant price target raised to DKK 258 from DKK 226 at Deutsche Bank

Julien Ouaddour

Bank of America Securities

CHF21.35→CHF35.16

Buy

―

Upgraded

06/09/26

Demant upgraded to Buy from Underperform at BofADemant upgraded to Buy from Underperform at BofA

Martin Brenoe

Nordea Markets

CHF28.88

Buy

―

Upgraded

02/18/26

Demant upgraded to Buy from Hold at NordeaDemant upgraded to Buy from Hold at Nordea

Andjela Bozinovic

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

CHF25.12

Hold

―

Downgraded

02/06/26

Demant downgraded to Neutral from Outperform at BNP ParibasDemant downgraded to Neutral from Outperform at BNP Paribas

David Adlington

J.P. Morgan

CHF36.17→CHF31.4

Buy

―

Reiterated

02/04/26

Demant price target lowered to DKK 250 from DKK 288 at JPMorganDemant price target lowered to DKK 250 from DKK 288 at JPMorgan

Jack Reynolds-Clark

RBC Capital

CHF31.4

Hold

―

Initiated

11/18/25

Demant initiated with a Sector Perform at RBC CapitalDemant initiated with a Sector Perform at RBC Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Demant

3 Months

Veronika DubajovaCiti

Success Rate

6/10 ratings generated profit

Average Return

+1.55%

Copying Veronika Dubajova's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +1.55% per trade.

1 Year

Veronika DubajovaCiti

Success Rate

8/10 ratings generated profit

Average Return

+13.40%

Copying Veronika Dubajova's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +13.40% per trade.

2 Years

Richard FeltonGoldman Sachs

Success Rate

6/7 ratings generated profit

Average Return

+19.63%

Copying Richard Felton's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +19.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WDH1 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

0

Buy

11

7

9

Hold

5

4

6

7

8

Sell

0

Strong Sell

0

total

16

11

13

14

17

In the current month, WDH1 has received 9 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. WDH1 average Analyst price target in the past 3 months is 36.55.

Each month's total comprises the sum of three months' worth of ratings.

WDH1 Financial Forecast

WDH1 Earnings Forecast

Next quarter’s earnings estimate for WDH1 is CHF0.92 with a range of CHF0.87 to CHF0.99. The previous quarter’s EPS was CHF0.80. WDH1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year WDH1 has Performed in-line its overall industry.

WDH1 Sales Forecast

Next quarter’s sales forecast for WDH1 is CHF1.67B with a range of CHF1.63B to CHF1.70B. The previous quarter’s sales results were CHF1.63B. WDH1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year WDH1 has Performed in-line its overall industry.

WDH1 Stock Forecast FAQ

What is CH:WDH1’s average 12-month price target, according to analysts?

Based on analyst ratings, Demant A/S’s 12-month average price target is 36.55.

What is CH:WDH1’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:WDH1, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Demant A/S a Buy, Sell or Hold?

Demant A/S has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 5 hold ratings and 0 sell ratings.

What is Demant A/S’s share price target?

The average share price target for Demant A/S is 36.55. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF43.33 ,and the lowest forecast is CHF32.40. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Demant A/S?

Demant A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Demant A/S?

To buy shares of CH:WDH1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Demant (WDH1) Stock Forecast & Price Target

WDH1 Analyst Ratings

WDH1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Demant

WDH1 Analyst Recommendation Trends

WDH1 Financial Forecast

WDH1 Earnings Forecast

WDH1 Sales Forecast

WDH1 Stock Forecast FAQ

Detailed List of Analyst Forecasts